SCHEMBL3230674

SCHEMBL3230674

CN(Cc1ccccc1)C(=O)c1ccc(C(C)(O)C(F)(F)F)cc1

nearest known ligand 0.78

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MLYCD O95822 3/20 0.78
MEN1 O00255 2/20 0.60
KMT2A Q03164 2/20 0.60
HDAC6 Q9UBN7 4/20 0.56
HDAC1 Q13547 3/20 0.56
HDAC4 P56524 3/20 0.53
HDAC3 O15379 2/20 0.53
HDAC7 Q8WUI4 1/20 0.53
HDAC2 Q92769 1/20 0.53
HDAC5 Q9UQL6 1/20 0.53
HSD11B1 P28845 3/20 0.52
LIMK2 P53671 2/20 0.51
MAOA P21397 1/20 0.51
ABL1 P00519 1/20 0.50
LCK P06239 1/20 0.50
LIMK1 P53667 1/20 0.50
PDK1 Q15118 1/20 0.49
MTOR P42345 1/20 0.49
NR1H3 Q13133 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2945131 0.88 MLYCD (1.00) MLYCDMEN1KMT2AHDAC6HDAC1
SCHEMBL13431498 0.87 MLYCD (0.79) MLYCDMEN1KMT2AHSD11B1NR1H3
SCHEMBL5645193 0.86 MEN1 (0.78) MLYCDMEN1KMT2AHDAC6HDAC1
SCHEMBL3234094 0.85 MLYCD (0.57) MLYCDMEN1KMT2AHDAC6HDAC1
SCHEMBL21923501 0.84 MLYCD (0.70) MLYCDMEN1KMT2AHDAC6HDAC1
SCHEMBL13431536 0.84 MLYCD (0.56) MLYCDMEN1KMT2AHDAC6HDAC1
SCHEMBL13431545 0.83 MLYCD (0.55) MLYCDMEN1KMT2AHDAC6HSD11B1
SCHEMBL13431535 0.81 HSD11B1 (0.64) HDAC6HDAC3HSD11B1
SCHEMBL1003665 0.79 KMT2A (0.83) MLYCDMEN1KMT2AHDAC6HDAC1
SCHEMBL5644792 0.78 LIMK2 (0.70) MLYCDMEN1KMT2AHDAC6HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8637576-B2 Benzamide derivatives and uses related thereto AMGEN INC. (US) 2014-01-28 US claimed
EP-1904435-B1 BENZAMIDE DERIVATIVES AND USES RELATED THERETO AMGEN INC (US) 2013-01-02 EP claimed
US-7605289-B2 Benzamide derivatives and uses related thereto AMGEN, INC. (US) 2009-10-20 US claimed
EP-1904435-A2 BENZAMIDE DERIVATIVES AND USES RELATED THERETO Amgen Inc. (US) 2008-04-02 EP claimed
WO-2006138508-A2 BENZAMIDE DERIVATIVES AND USES RELATED THERETO AMGEN INC. (US) 2006-12-28 WO claimed
US-20060293392-A1 Benzamide derivatives and uses related thereto AMGEN INC. 2006-12-28 US claimed
US-8637576-B2 Benzamide derivatives and uses related thereto AMGEN INC. (US) 2014-01-28 US disclosed
US-8637576-B2 Benzamide derivatives and uses related thereto AMGEN INC. (US) 2014-01-28 US disclosed
US-8637576-B2 Benzamide derivatives and uses related thereto AMGEN INC. (US) 2014-01-28 US disclosed
EP-1904435-B1 BENZAMIDE DERIVATIVES AND USES RELATED THERETO AMGEN INC (US) 2013-01-02 EP disclosed
EP-1904435-B1 BENZAMIDE DERIVATIVES AND USES RELATED THERETO AMGEN INC (US) 2013-01-02 EP disclosed
US-20100069447-A1 BENZAMIDE DERIVATIVES AND USES RELATED THERETO AMGEN INC. 2010-03-18 US disclosed
US-20100069447-A1 BENZAMIDE DERIVATIVES AND USES RELATED THERETO AMGEN INC. 2010-03-18 US disclosed
US-7605289-B2 Benzamide derivatives and uses related thereto AMGEN, INC. (US) 2009-10-20 US disclosed
US-7605289-B2 Benzamide derivatives and uses related thereto AMGEN, INC. (US) 2009-10-20 US disclosed
US-7605289-B2 Benzamide derivatives and uses related thereto AMGEN, INC. (US) 2009-10-20 US disclosed
EP-1904435-A2 BENZAMIDE DERIVATIVES AND USES RELATED THERETO Amgen Inc. (US) 2008-04-02 EP disclosed
US-20060293392-A1 Benzamide derivatives and uses related thereto AMGEN INC. 2006-12-28 US disclosed
WO-2006138508-A2 BENZAMIDE DERIVATIVES AND USES RELATED THERETO AMGEN INC. (US) 2006-12-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060293392-A1 Benzamide derivatives and uses related thereto GPR119, GLP1R, UGT2B7 MLYCD 896/4885MEN1 2543/4885KMT2A 1365/4885
US-20100069447-A1 BENZAMIDE DERIVATIVES AND USES RELATED THERETO GPR119, GLP1R, UGT2B7 MLYCD 896/4885MEN1 2543/4885KMT2A 1365/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.